US · Healthcare · Biotechnology
EPS came in at -0.17 against a street estimate of -0.18 — a beat of 5.6%.
Analysts rate Black Diamond Therapeutics Inc a strong buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $10.00.
| Fund | Stake |
|---|---|
| NEA Management Company, LLC | 7.74% |
| T. Rowe Price Investment Management,Inc. | 7.01% |
| BlackRock Inc | 6.82% |
| Acadian Asset Management LLC | 4.09% |
| Vanguard Capital Management, LLC | 3.70% |
| Renaissance Technologies Corp | 3.42% |
| Defilade Capital Management, L.P. | 2.92% |
| Dimensional Fund Advisors, Inc. | 2.38% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Black Diamond Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.